Sökning: "Rolf Larsson"
Visar resultat 21 - 25 av 54 avhandlingar innehållade orden Rolf Larsson.
21. Why did the Riksbank miss its target? A Swedish Phillips curve
Sammanfattning : .... LÄS MER
22. Preclinical Development of New Alkylating Oligopeptides for Cancer Therapy
Sammanfattning : Oligopeptides can be used to carry cytotoxic agents in cancer chemotherapy, using tumour-associated proteins as the molecular target for selectivity. During the seventies and eighties Peptichemio, a cocktail of six alkylating oligopeptides carrying m-L-sarcolysin, was investigated in a wide variety of human malignancies. LÄS MER
23. Integrating Efficacy and Toxicity in Preclinical Anticancer Drug Development : Methods and Applications
Sammanfattning : Preclinical testing is an important part of cancer drug development. The aim of this thesis was to establish and evaluate preclinical in vitro methods useful in the development of new anticancer drugs. In paper I, the development of non-clonogenic assays (FMCA-GM) using CD34+ stem cells for assessment of haematological toxicity was described. LÄS MER
24. Methods for Preclinical Evaluation of Cytotoxic Drugs : With Special Reference to the Cyanoguanidine CHS 828 and Hollow Fiber Method
Sammanfattning : The novel cyanoguanidine CHS 828 has shown promising antitumor activity in many in vitro and in vivo studies. The long-term 14 days in vitro hollow fiber cultures, where tumor cells from different tumor cell lines were cultured inside semipermeable fibers, were more resistant to CHS 828 and other cytotoxic drugs than the shorter-term 3 days cultures. LÄS MER
25. Preclinical and Clinical Development of the Novel Cyanoguanidine CHS 828 for Cancer Treatment
Sammanfattning : CHS 828 is a cyanoguanidine with anti-tumour properties which has shown promising effects in several preclinical models. This thesis describes both preclinical and clinical studies aiming to investigate disease specific activity, clinical tolerability and efficacy of CHS 828. LÄS MER